Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
Ying Li,Jia-Jing Lu,Xiao-Yuan Zhong,Ying-Yuan Yu,Ning Yu,Yu Wang,Xue-Mei Yi,Yang-Feng Ding,Yu-Ling Shi
DOI: https://doi.org/10.2147/CCID.S387759
2022-10-20
Abstract:Ying Li 1, 2 &ast, Jia-Jing Lu 1, 2 &ast, Xiao-Yuan Zhong 1, 2 &ast, Ying-Yuan Yu 1, 2 &ast, Ning Yu, 1, 2 Yu Wang, 1, 2 Xue-Mei Yi, 1, 2 Yang-Feng Ding, 1, 2 Yu-Ling Shi 1, 2 1 Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China; 2 Institute of Psoriasis, Tongji University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yu-Ling Shi; Yang-Feng Ding, Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, 1278 Road, Shanghai, 200443, People's Republic of China, Email ; Background: Data pertaining to biologic agents used for treating psoriasis in real-world settings are lacking at present. To compare drug survival at 52 weeks for a range of biologics used to treat psoriasis under real-world conditions. Methods: This was a retrospective, single-center, observational study of a cohort of patients diagnosed with plaque psoriasis treated using ixekizumab, secukinumab, guselkumab, or adalimumab between January 2020 and December 2021. Baseline demographic characteristics, duration of psoriasis, and prior biological treatments for all patients were recorded. Drug survival rates were analyzed in different patient groups using Kaplan–Meier curves and Log rank tests. Results: In total, this study included 386 plaque psoriasis patients, of whom 70, 175, 36, and 105 were, respectively, treated using ixekizumab, secukinumab, guselkumab, and adalimumab. Over a 52-week period, the overall cumulative drug survival rates for ixekizumab, secukinumab, guselkumab, and adalimumab were 67.1%, 63.0%, 72.2%, and 37.1%, respectively. Lack of efficacy was the primary cause of discontinuation for these biologic therapies, followed by economic burden and adverse event incidence. Conclusion: These results suggest that guselkumab exhibited superior drug survival, drug survival outcomes for ixekizumab and secukinumab were comparable, and significantly better than those of adalimumab in China. Preventing a loss of drug efficacy represents a primary approach to improving biologic drug survival in psoriasis patients. Keywords: biologics, drug survival, real-world, psoriasis, ixekizumab, secukinumab, guselkumab, adalimumab Psoriasis is a chronic inflammatory cutaneous condition that impacts roughly 125 million people throughout the world, can occur at any age, and is characterized by the recurrent development of erythematous scales. 1 Biological agents have achieved great success in the management of patients suffering from moderate-to-severe plaque psoriasis, with IL-17 or IL-23 targeting antibody inhibitors including secukinumab, ixekizumab, and guselkumab having shown marked efficacy in Phase 3 clinical trials comparing them to biologics targeting TNF-α. 2–4 Despite their excellent efficacy, however, psoriasis patients undergoing biologic treatment regimens often discontinue treatment or switch to other biologics for a variety of reasons in clinical practice. Drug survival has been shown to offer value as a means of assessing the efficacy of biologic treatments for psoriasis in real-world settings, 5 and can be impacted by many factors including safety, cost, convenience, therapeutic efficacy, and the incidence of side effects. However, the available real-world data pertaining to biologic drug survival in psoriasis patients are limited, and results are sometimes inconsistent across studies. 6,7 Relative to other countries, the approval of biologics for treating psoriasis is relatively recent, and there is thus a limited amount of real-world data regarding drug survival outcomes. The present study was developed to assess drug survival among Chinese psoriasis patients undergoing treatment using ixekizumab, secukinumab, guselkumab, and adalimumab, and to assess factors with the potential to impact drug survival over a 52-week follow-up period. This was a retrospective, observational, and single-center analysis of a cohort of chronic plaque psoriasis patients with or without psoriatic arthritis (PsA). For this study, medical records for all individuals with moderate-to-severe psoriasis that underwent ixekizumab, secukinumab, guselkumab, or adalimumab treatment from January 2020-December 2021 at Shanghai Skin Disease Hospital were reviewed. The patients included were moderate to severe plaque psoriasis, aged ≥ 18 years old, and patients were excluded if they exhibited pustular psoriasis or erythroder -Abstract Truncated-